Aviragen pipeline

Aviragen Therapeutics is focused on the discovery and development of next generation direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three drugs in Phase 2 clinical development: These include vapendavir, a capsid inhibitor in a Phase 2b trial for the treatment of human rhinovirus infections in moderate-to-severe asthmatics; BTA585, a fusion protein inhibitor in a Phase 2a respiratory syncytial virus challenge study in healthy volunteers; and BTA074, a topical gel in a Phase 2 trial in patients with condyloma caused by human papillomavirus.


  • georgia-bio-life      deloitte-fast-500

Log In

Create an account